Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/20384
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRegan, Meredith M
dc.contributor.authorPagani, Olivia
dc.contributor.authorFrancis, Prudence A
dc.contributor.authorFleming, Gini F
dc.contributor.authorWalley, Barbara A
dc.contributor.authorKammler, Roswitha
dc.contributor.authorDell'Orto, Patrizia
dc.contributor.authorRusso, Leila
dc.contributor.authorSzőke, János
dc.contributor.authorDoimi, Franco
dc.contributor.authorVillani, Laura
dc.contributor.authorPizzolitto, Stefano
dc.contributor.authorÖhlschlegel, Christian
dc.contributor.authorSessa, Fausto
dc.contributor.authorPeg Cámara, Vicente
dc.contributor.authorRodríguez Peralto, José Luis
dc.contributor.authorMacGrogan, Gaëtan
dc.contributor.authorColleoni, Marco
dc.contributor.authorGoldhirsch, Aron
dc.contributor.authorPrice, Karen N
dc.contributor.authorCoates, Alan S
dc.contributor.authorGelber, Richard D
dc.contributor.authorViale, Giuseppe
dc.date.accessioned2019-06-28T12:55:03Z-
dc.date.available2019-06-28T12:55:03Z-
dc.date.issued2015-11
dc.identifier.citationBreast Cancer Res. Treat..2015 Nov;(154)2:275-86
dc.identifier.urihttps://hdl.handle.net/20.500.12530/20384-
dc.description.abstractThe SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and predictive value of centrally assessed levels of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67 expression in women with HER2-negative disease. Of 5707 women enrolled, 4115 with HER2-negative (HR+/HER2-) disease had ER, PgR, and Ki-67 centrally assessed by immunohistochemistry. Breast cancer-free interval (BCFI) was defined from randomization to first invasive local, regional, or distant recurrence or contralateral breast cancer. The prognostic and predictive values of ER, PgR and Ki-67 expression levels were assessed using Cox modeling and STEPP methodology. In this HR+/HER2- population, the median ER, PgR, and Ki-67 expressions were 95, 90, and 18 % immunostained cells. As most patients had strongly ER-positive tumors, the predictive value of ER levels could not be investigated. Lower PgR and higher Ki-67 expression were associated with reduced BCFI. There was no consistent evidence of heterogeneity of the relative treatment effects according to PgR or Ki-67 expression levels, though there was a greater 5-year absolute benefit of exemestane + ovarian function suppression (OFS) versus tamoxifen with or without OFS at lower levels of PgR and higher levels of Ki-67. Women with poor prognostic features of low PgR and/or high Ki-67 have greater absolute benefit from exemestane + OFS versus tamoxifen + OFS or tamoxifen alone, but individually PgR and Ki-67 are of limited predictive value for selecting adjuvant endocrine therapy for premenopausal women with HR+/HER2- early breast cancer.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectEstrogen receptor
dc.subjectExemestane
dc.subjectKi-67
dc.subjectOvarian function suppression
dc.subjectProgesterone receptor
dc.subjectTamoxifen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshBiomarkers, Tumor
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshClinical Trials, Phase III as Topic
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshKi-67 Antigen
dc.subject.meshLymphatic Metastasis
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Grading
dc.subject.meshPremenopause
dc.subject.meshPrognosis
dc.subject.meshProportional Hazards Models
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshReceptor, ErbB-2
dc.subject.meshReceptors, Estrogen
dc.subject.meshReceptors, Progesterone
dc.subject.meshTumor Burden
dc.subject.meshYoung Adult
dc.titlePredictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
dc.typeArtículo
dc.identifier.pubmedID26493064
dc.format.volume154
dc.format.page275-86
dc.identifier.e-issn1573-7217
dc.identifier.journalBreast cancer research and treatment
dc.identifier.doi10.1007/s10549-015-3612-z
dc.format.number2
dc.identifier.pmcPMC4749471
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, N.I.H., Extramural
dc.pubmedtypeResearch Support, Non-U.S. Gov't
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
PMC4749471.pdf1.1 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.